作者:Xiaozhen Wang、Yuji Wang、Jianhui Wu、Lin Gui、Xiaoyi Zhang、Meiqing Zheng、Yaonan Wang、Shurui Zhao、Ze Li、Ming Zhao、Shiqi Peng
DOI:10.1016/j.bmcl.2017.10.068
日期:2017.12
In GPIIb/IIIa mediated arterial thrombosis platelet activation plays a central role. To discover platelet activation inhibitor the pharmacophores of GPIIb/IIIa receptor inhibitors and anti-thrombotic agents were analyzed. This led to the design of (1R,3S)- and (1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acids as GPIIb/IIIa inhibitors. Comparing to (1S,3S)-isomer (1R,3S)-isomer had
在GPIIb / IIIa介导的动脉血栓形成中,血小板活化起着核心作用。为了发现血小板活化抑制剂,分析了GPIIb / IIIa受体抑制剂和抗血栓形成剂的药效团。这导致设计了(1 R,3 S)-和(1 S,3 S)-1-甲基-1,2,3,4-四氢-β-咔啉-3-羧酸作为GPIIb / IIIa抑制剂。与(1 S,3 S)-异构体相比(1 R,3 S)-异构体具有较低的cdocker相互作用能。AFM图像显示(1 S,3 S)-异构体和(1 R,3 S)-异构体抑制血小板活化分别为10 -5 M和10 -6M 。体内1μmol/ kg口服(1 S,3 S)异构体可有效抑制大鼠形成动脉血栓并下调GPIIb / IIIa表达,但活性明显低于1μmol/ kg口服(1 S,3 S)异构体(1 R,3S)-异构体。(1 S,3 S)-异构体和(1 R,3 S)-异构体均可安全用于结构修饰,但(1